A Phase 3 interventional study of Azilsartan medoxomil/placebo and Azilsartan medoxomil - chlorthalidone in Essential Hypertension, sponsored by Takeda. Completed at 108 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-23.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Essential Hypertension by Takeda — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Takeda.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 12 in phase 3, and was the 11th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 15 studies in Essential Hypertension by Takeda is open now. The open studies under Essential Hypertension, anywhere →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 669 across the 15 interventional studies. Of the 15 that completed or were terminated, 14 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Essential Hypertension by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg), once daily, in participants with grades 2 or 3 essential hypertension who do not reach target blood pressure following treatment with 40 mg azilsartan medoxomil monotherapy after 4 weeks.
Eligible participants completed a 2-week single-blind run-in period (Days -42 to -29) prior to a Single-Blind Monotherapy Treatment Period (Day -28 to Day -1) where they received azilsartan medoxomil 40 mg. After the Single-Blind Monotherapy Treatment Period, those participants who achieved target blood pressure discontinued treatment and resumed standard of care management at the discretion of their treating physician, while those participants who did not achieve target blood pressure (defined as clinic systolic blood pressure ≥140 mmHg) were randomly assigned to 1 of 3 active treatment arms: azilsartan medoxomil 40 mg plus placebo, azilsartan medoxomil plus chlorthalidone 40/12.5 mg, or azilsartan medoxomil plus chlorthalidone 40/25 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Screening
The participant has grade 2-3 essential hypertension which is not adequately controlled, as defined by mean, trough, sitting, clinic systolic blood pressure (SBP):
A female of who is sexually active with a nonsterilized male partner agrees to routinely use adequate from signing of the informed consent through 30 days after the last study drug dose. NOTE: Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation [performed more than one 1 year prior to Screening]) or who are (defined as at least 1 year since last regular menses).
Post-placebo run-in:
The participant must have a post-placebo run-in, 24-hour mean SBP by ambulatory blood pressure monitoring (ABPM) of 140-175 mm Hg inclusive, and a clinic SBP measurement of 160 to 190 mm Hg inclusive (determined by the mean of 3 sitting, trough, measurements on Day -29) to qualify for entry in to the 4 week single-blind TAK-491 40 mg monotherapy treatment period.
Post-4 week, single-blind TAK-491 40 mg monotherapy treatment:
Exclusion Criteria:
At Screening
If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
Post-placebo run-in period
The participant has a 24-hour mean eligibility ABPM reading of insufficient quality.
Post-single-blind TAK-491 40 mg treatment period
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
Drug: Azilsartan medoxomil/placebo
Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
Drug: Azilsartan medoxomil - chlorthalidone
Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
Drug: Azilsartan medoxomil - chlorthalidone
Azilsartan medoxomil and placebo to chlorthalidone combination tablets
Also known as: TAK-491, EDARBI
Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
Also known as: TAK-491CLD, Edarbyclor
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure
The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline (of the double-blind treatment period) and Week 8
Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure
The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8, 22-24 hours after dosing
Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8, 22-24 hours after dosing
Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring
The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring
The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 8
Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8
Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements.
Time frame: Week 8
Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8
Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Week 8
Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8
Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure.
Time frame: Week 8
A total of 1754 patients were screened at 125 investigative sites in Bulgaria, Estonia, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Serbia, Slovakia, Spain, Sweden, and the United Kingdom from 31 October 2011 to 24 January 2013.
| Milestone | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Started | 133 | 127 | 135 |
| Completed | 123 | 122 | 123 |
| Not completed | 10 | 5 | 12 |
| Withdrew: Adverse event | 1 | 2 | 7 |
| Withdrew: Major protocol deviation | 3 | 2 | 3 |
| Withdrew: Voluntary withdrawal | 3 | 0 | 2 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 |
The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 150.7 ± 0.96 | 149.8 ± 0.98 | 149.8 ± 0.95 |
| Change from Baseline to Week 8 | -6.4 ± 1.05 | -15.8 ± 1.08 | -21.1 ± 1.04 |
The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 89.8 ± 0.73 | 87.7 ± 0.75 | 88.8 ± 0.72 |
| Change from Baseline to Week 8 | -3.2 ± 0.65 | -7.7 ± 0.67 | -10.3 ± 0.65 |
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 143.1 ± 1.55 | 140.2 ± 1.62 | 142.0 ± 1.58 |
| Change from Baseline to Week 8 | -2.5 ± 1.31 | -14.0 ± 1.36 | -16.6 ± 1.32 |
The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 86.4 ± 1.11 | 83.6 ± 1.16 | 86.0 ± 1.12 |
| Change from Baseline to Week 8 | -2.2 ± 0.88 | -8.8 ± 0.92 | -9.4 ± 0.89 |
The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 138.0 ± 1.21 | 137.0 ± 1.26 | 138.2 ± 1.22 |
| Change from Baseline to Week 8 | -2.3 ± 1.02 | -14.7 ± 1.07 | -18.1 ± 1.03 |
The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 81.9 ± 0.89 | 80.3 ± 0.93 | 82.5 ± 0.91 |
| Change from Baseline to Week 8 | -1.6 ± 0.66 | -8.5 ± 0.69 | -10.1 ± 0.67 |
The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 141.5 ± 1.24 | 141.1 ± 1.30 | 141.9 ± 1.26 |
| Change from Baseline to Week 8 | -2.4 ± 1.09 | -15.3 ± 1.14 | -18.2 ± 1.11 |
The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 84.9 ± 0.96 | 83.6 ± 1.01 | 85.7 ± 0.98 |
| Change from Baseline to Week 8 | -1.7 ± 0.72 | -8.9 ± 0.75 | -10.1 ± 0.73 |
The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 127.3 ± 1.50 | 124.2 ± 1.57 | 126.3 ± 1.52 |
| Change from Baseline to Week 8 | -2.2 ± 1.18 | -12.7 ± 1.24 | -17.3 ± 1.20 |
The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 73.2 ± 0.95 | 70.6 ± 0.99 | 72.9 ± 0.97 |
| Change from Baseline to Week 8 | -1.6 ± 0.78 | -7.2 ± 0.82 | -9.8 ± 0.79 |
The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 141.6 ± 1.30 | 141.8 ± 1.36 | 142.3 ± 1.32 |
| Change from Baseline to Week 8 | -2.3 ± 1.14 | -15.4 ± 1.19 | -18.2 ± 1.16 |
The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mm Hg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Baseline | 85.2 ± 1.01 | 84.2 ± 1.05 | 86.0 ± 1.02 |
| Week 8 | -1.6 ± 0.75 | -8.9 ± 0.78 | -10.1 ± 0.76 |
Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8 | 35.3 | 62.7 | 77.8 |
Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8 | 60.2 | 81.0 | 85.9 |
Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure.
| percentage of participants | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|
| Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8 | 30.8 | 59.5 | 74.1 |
Collected over For 4 weeks during the monotherapy treatment period and from the first dose of double-blind study drug up to 14 days (or 30 days for a Serious AE) after the last dose of study drug in the 8-week double-blind treatment period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy: Azilsartan Medoxomil 40 mg | — | 3/507 (0.6%) | 15/507 (3%) |
| Azilsartan Medoxomil 40 mg | — | 2/133 (1.5%) | 15/133 (11.3%) |
| Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | — | 0/127 (0%) | 13/127 (10.2%) |
| Azilsartan Medoxomil + Chlorthalidone 40/25 mg | — | 0/135 (0%) | 26/135 (19.3%) |
| Event | Monotherapy: Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/507 | 1/133 | 0/127 | 0/135 |
| Cerebrovascular accidentNervous system disorders | 1/507 | 1/133 | 0/127 | 0/135 |
| Acute myocardial infarctionCardiac disorders | 1/507 | 0/133 | 0/127 | 0/135 |
| Ventricular tachycardiaCardiac disorders | 1/507 | 0/133 | 0/127 | 0/135 |
| Blood pressure increasedInvestigations | 1/507 | 0/133 | 0/127 | 0/135 |
| Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/507 | 0/133 | 0/127 | 0/135 |
| Event | Monotherapy: Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg |
|---|---|---|---|---|
| Blood creatinine increasedInvestigations | 2/507 | 4/133 | 4/127 | 11/135 |
| DizzinessNervous system disorders | 3/507 | 0/133 | 2/127 | 6/135 |
| HeadacheNervous system disorders | 9/507 | 2/133 | 3/127 | 5/135 |
| NasopharyngitisInfections and infestations | 6/507 | 4/133 | 2/127 | 4/135 |
| Viral infectionInfections and infestations | 0/507 | 4/133 | 0/127 | 0/135 |
| HypotensionVascular disorders | 0/507 | 1/133 | 2/127 | 4/135 |
Participants who were randomized into the double-blind treatment period. Baseline was defined as the last observed value while on monotherapy study drug and before the first dose of double-blind study drug.
| Age, Continuous(years) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| Mean | 57.9 ± 10.18 | 59.2 ± 10.72 | 57.7 ± 10.46 | 58.2 ± 10.45 |
| Age, Customized(participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| < 45 years | 13 | 10 | 12 | 35 |
| 45 to < 65 years | 87 | 79 | 88 | 254 |
| ≥ 65 years | 33 | 38 | 35 | 106 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| Female | 46 | 54 | 44 | 144 |
| Male | 87 | 73 | 91 | 251 |
| Race/Ethnicity, Customized(participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| White | 132 | 126 | 134 | 392 |
| Multiracial | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| Bulgaria | 11 | 10 | 11 | 32 |
| Estonia | 18 | 16 | 18 | 52 |
| France | 2 | 1 | 2 | 5 |
| Germany | 29 | 29 | 28 | 86 |
| Hungary | 10 | 9 | 10 | 29 |
| Italy | 6 | 4 | 5 | 15 |
| Lithuania | 5 | 4 | 6 | 15 |
| Netherlands | 4 | 6 | 5 | 15 |
| Poland | 17 | 18 | 17 | 52 |
| Serbia | 4 | 3 | 4 | 11 |
| Slovakia | 24 | 24 | 26 | 74 |
| Spain | 1 | 1 | 1 | 3 |
| Sweden | 1 | 2 | 1 | 4 |
| United Kingdom | 1 | 0 | 1 | 2 |
| Weight(kg) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| Mean | 87.59 ± 15.794 | 86.71 ± 17.037 | 87.39 ± 14.876 | 87.24 ± 15.868 |
| Height(cm) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| Mean | 171.8 ± 8.87 | 170.6 ± 9.96 | 172.1 ± 9.74 | 171.5 ± 9.53 |
| Body Mass Index (BMI)(kg/m^2) | Azilsartan Medoxomil 40 mg | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Total |
|---|---|---|---|---|
| Mean | 29.63 ± 5.066 | 29.78 ± 5.206 | 29.52 ± 4.572 | 29.64 ± 4.937 |
8 further baseline measures are reported on the registry.
Showing the first 100 of 108 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2011, a primary completion of Dec 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.